Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin's Lymphoma

Summary of Two Important Lymphoma Studies - POLARIX andd SWOG S1826 #oncology #cancer #LymphomaПодробнее

Polatuzumab FDA Approval in DLBCL (POLARIX) & SWOG S1826 Nivo vs. BV in Hodgkin's LymphomaПодробнее

SWOG S1826 Study Design Discussion in Hodgkin's Lymphoma Patients #oncology #cancer #2023Подробнее

Genentech - FDA Approval of Polivy ® Combination for Treatment of Certain Types of Previously UntreПодробнее

Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHLПодробнее

SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphomaПодробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

Results of POLARIX Trial #oncology #cancer #2023Подробнее

Results of SWOG S1826 Study, showing Nivo-AVD better than BV-AVD in Hodgkin's Lymphoma patientsПодробнее

DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023Подробнее

POLARIX lymphoma trial debateПодробнее

ADC polatuzumab vedotin in combinations for relapsed lymphomaПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphomaПодробнее

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCLПодробнее

Nivolumab-AVD improved PFS versus brentuximab vedotin-AVD in patients with advanced stage HLПодробнее

POLARIX study: frontline therapy in DLBCLПодробнее

The Polarix Trial: Initial Therapy of Diffuse Large B-cell LymphomaПодробнее

Polatuzumab vedotin combined with R-ICE as second-line therapy in R/R diffuse large B-cell lymphomaПодробнее

Polatuzumab in Diffuse Large B-cell lymphomaПодробнее